Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$99.27 USD

99.27
4,182,726

+1.56 (1.60%)

Updated May 31, 2024 04:00 PM ET

After-Market: $99.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

by Zacks Equity Research

Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.

Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

by Zacks Equity Research

Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.

Should Value Investors Buy Cardinal Health (CAH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Reasons to Hold Patterson Companies (PDCO) in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Here's Why You Should Hold McKesson (MCK) in Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

3 Reasons Growth Investors Will Love Cardinal (CAH)

by Zacks Equity Research

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford

by Zacks Equity Research

GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.

UnitedHealth (UNH) Faces Investigation Following Cyberattack

by Zacks Equity Research

A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Revvity's (RVTY) New Launch to Boost Research Productivity

by Zacks Equity Research

Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).

Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA

by Zacks Equity Research

Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.

HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

by Zacks Equity Research

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Here's Why Cardinal Health (CAH) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

by Zacks Equity Research

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Align Technology (ALGN) Gains From Innovation, Macro Issues Ail

by Zacks Equity Research

In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.